NCT01170936View on ClinicalTrials.gov

Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

December 31, 2011

Conditions
UrticariaVasculitis
Interventions
DRUG

canakinumab

Single dose of canakinumab 300mg s.c. injection

Trial Locations (1)

10117

Charité-Universitätsmedizin Berlin, Berlin

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Charite University, Berlin, Germany

OTHER